Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies

When Sanjaya Singh left Johnson & Johnson in 2021, his former colleague Peter Lebowitz paid close attention.

Singh had been a mainstay in the immunology and oncology fields, helping to invent the blockbuster drug Skyrizi and several other treatments during stints at Johnson & Johnson and Boehringer Ingelheim. “If Sanjaya Singh is doing something, you want to watch it,” Lebowitz said. Perhaps there would be a good opportunity for a partnership. But last year, Singh and venture capital firm Omega Funds approached him with a different idea: Join the new biotech they were building as its chief executive officer.

“It was a no-brainer,” Lebowitz said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In